Real-life use of isavuconazole in Spanish children and adolescents
Authors:
- Natalia Mendoza-PalomarNMNatalia Mendoza-Palomar
- Silvia Simó NebotSilvia Simó Nebot
- Laura Roig-SoriaLRLaura Roig-Soria
- Laura Alonso GarcíaLGLaura Alonso García
- Marta Taida García AscasoMAMarta Taida García Ascaso
- David Díaz PérezDPDavid Díaz Pérez
- Carlos Grasa LozanoCLCarlos Grasa Lozano
- Cristina Jiménez NúñezCNCristina Jiménez Núñez
- Elena María Rincón LópezELElena María Rincón López
- Maria Luisa Navarro GómezMGMaria Luisa Navarro Gómez
- Begoña Carazo GallegoBGBegoña Carazo Gallego
Open Access
- 22 October 2025
- journal article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (1)
Abstract
Background and Objectives: Isavuconazole (ISA) has been recently approved for the treatment of invasive aspergillosis and mucormycosis in patients aged >1 year. Prior to this approval, it was used in paediatric patients under compassionate use. The objective of this study is to describe the experience with ISA use in children. Patients and methods: A descriptive, retrospective, multicentre study conducted in nine Spanish hospitals, including patients aged ≤18 years who received ≥7 days of ISA between 2018 and 2023. Therapeutic drug monitoring (TDM) was performed with pre-dose [trough concentration (Ctrough)] levels measured according to local protocols. A therapeutic range of 2.5–5 mg/L was used for analysis. Results: A total of 107 patients (median age: 11 years, 56% male) were included. ISA was used as a treatment (95 patients), mostly as second-line therapy (64 patients, 67%), due to toxicity from previous antifungals (27 patients, 42%). Of 53 patients with proven/probable invasive fungal disease (IFD), 32 (60%) showed a favourable response and 21 (40%) died, 13 due to IFD. Twelve patients received ISA as prophylaxis and none developed breakthrough IFD. Overall, 27/107 (25%) patients experienced adverse effects, the most common being hepatotoxicity, with 10 requiring discontinuation. TDM was performed in 76/95 patients (80%), revealing 59% of Ctrough values outside the therapeutic range. Conclusions: ISA appears to be a safe and effective option for treating IFD in children, especially when first-line agents have failed or caused excessive toxicity. Although no correlation between Ctrough and clinical outcomes was observed, the significant proportion of patients with out-of-range Ctrough emphasizes the need for TDM in paediatrics.Keywords
Funding Information
- European Society of Paediatric Infectious Diseases
- Spanish Ministry of Science and Innovation—Instituto de Salud Carlos III and Fondos FEDER (JR22/00044)
This publication has 37 references indexed in Scilit:
- Documento nacional de consenso de monitorización terapéutica de antibióticos y antifúngicos en el paciente pediátrico y neonatal de la Sociedad Española de Farmacia Hospitalaria (SEFH) y la Sociedad Española de Infectología Pediátrica (SEIP)Anales de Pediatría, 2024
- Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research ConsortiumClinical Infectious Diseases, 2019
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Successful treatment of invasive mucormycosis with isavuconazole in pediatric patientsPediatric Blood & Cancer, 2018
- Diagnosis of invasive fungal diseases in pediatric patientsExpert Review of Anti-infective Therapy, 2016
- Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysisThe Lancet Infectious Diseases, 2016
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2016
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trialThe Lancet, 2016
- Isavuconazole: A New Broad-Spectrum Triazole Antifungal AgentClinical Infectious Diseases, 2015
- Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus CriteriaClinical Infectious Diseases, 2008